SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced its intention
to offer, subject to market and other conditions, senior unsecured notes
under a shelf registration statement on Form S-3 on file with the
Securities and Exchange Commission. The interest rate, the maturity
dates and other key terms of the offering are to be determined at the
time of pricing.
Celgene expects to use the net proceeds from the offering to finance a
portion of the acquisition of Juno Therapeutics, Inc. and to pay fees
and expenses associated therewith and with the offering.
Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P.
Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith
Incorporated are acting as joint book-running managers and
representatives of the several underwriters. A copy of the preliminary
prospectus supplement and the accompanying base prospectus, which is
filed as part of Celgene's effective shelf registration statement on
Form S-3 (File No. 333-214279), may be obtained from any of the
representatives by calling Citigroup Global Markets Inc. at
1-800-831-9146, Deutsche Bank Securities Inc. at 1-800-503-4611, J.P.
Morgan Securities LLC at 1-212-834-4533 and Merrill Lynch, Pierce,
Fenner & Smith Incorporated at 1-800-294-1322.
An electronic copy of the preliminary prospectus supplement and the
accompanying base prospectus may also be obtained at no charge at the
Securities and Exchange Commission's website at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the notes described herein, nor shall
there be any sale of these notes in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the laws of such jurisdiction. The offering of
the notes will be made only by means of a prospectus supplement and the
accompanying base prospectus.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Hyperlinks are provided as a convenience and for informational purposes
only. Celgene bears no responsibility for the security or content of
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208005779/en/
Source: Celgene Corporation
News Provided by Acquire Media